Fact check · Version 1 · Sources checked
“Abaloparatide reduced fractures in a randomized phase 3 trial.”
The Peptide Field explains research. Its pages are not independently medically reviewed, and they do not diagnose, prescribe, or recommend treatment.
Supported with scope
The reviewed evidence supports this exact statement only in the situation described below.
ACTIVE found fewer new vertebral and nonvertebral fractures versus placebo in postmenopausal women with osteoporosis.
- What this answer is based on
- This answer uses a study that assigned people to groups by chance and measured a health outcome.
- Limits of this answer
- Postmenopausal women with osteoporosis at fracture risk over 18 months. These limits show which substance, product, people, use, place, and time the answer covers. A different product or situation can have a different answer.
- Topic
- What a study measured about people's health, symptoms, or ability to function.
Sources for this fact check
Show 1 sources
- Sources checked by
- Site editor · Editorial review